FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Annick Desjardins

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Emil Lou; Katherine B Peters; David A Reardon; Ashley L Sumrall; Scott Turner; Leighann Bailey; April Coan; Annick Desjardins; Henry S Friedman; James E Herndon; Eric S Lipp; James J Vredenburgh
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
David A Reardon; Jeremy Rich; John H Sampson; Sith Sathornsumetee; A L Sumrall; S Turner; Darell D Bigner; S T Boulton; A Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; E S Lipp; E Lou; K B Peters; James J Vredenburgh
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
David A Reardon; Jeremy N Rich; Sith Sathornsumetee; James J Vredenburgh; Sridharan Gururangan; James E Herndon; Dorothea Janney; Eric S Lipp; Roger McLendon; Katherine B Peters; April Coan; Annick Desjardins; Henry S Friedman
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Annick Desjardins (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emil Lou; Katherine B Peters; David A Reardon; Ashley L Sumrall; Scott Turner; Leighann Bailey; April Coan; Annick Desjardins; Henry S Friedman; James E Herndon; Eric S Lipp; James J Vredenburgh
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Cancer medicine 2013;2(2):185-95.
2012: David A Reardon; Jeremy Rich; John H Sampson; Sith Sathornsumetee; A L Sumrall; S Turner; Darell D Bigner; S T Boulton; A Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; E S Lipp; E Lou; K B Peters; James J Vredenburgh
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
British journal of cancer 2012;107(9):1481-7.
2012: David A Reardon; Jeremy N Rich; Sith Sathornsumetee; James J Vredenburgh; Sridharan Gururangan; James E Herndon; Dorothea Janney; Eric S Lipp; Roger McLendon; Katherine B Peters; April Coan; Annick Desjardins; Henry S Friedman
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Cancer 2012;118(19):4759-67.
2012: Emil Lou; Roger E McLendon; Frances McSherry; Julie Norfleet; Katherine B Peters; Annick Desjardins; Henry S Friedman; James E Herndon; Ashley L Sumrall; Scott Turner; James J Vredenburgh; David A Reardon
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Journal of neuro-oncology 2012;109(1):63-70.
2012: Annick Desjardins; Henry S Friedman
Neuro-oncology: Glioblastoma--community adjusts to new standard of care.
Nature reviews. Neurology 2012;8(5):244-6.
2012: Kyle C Cuneo; Annick Desjardins; Henry S Friedman; Katherine B Peters; David A Reardon; John H Sampson; James J Vredenburgh; Christopher G Willett; John P Kirkpatrick
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
International journal of radiation oncology, biology, physics 2012;82(5):2018-24.
2012: David A Reardon; John H Sampson; Stevie Threatt; James J Vredenburgh; Anuradha Bulusu; Annick Desjardins; Allan H Friedman; Sridharan Gururangan; James E Herndon; Roger E McLendon; Katherine B Peters; Henry S Friedman
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Journal of neuro-oncology 2012;107(1):155-64.
2012: Annick Desjardins; Henry S Friedman; James E Herndon; Jennifer Marcello; Katherine B Peters; David A Reardon; Leighann Bailey; April Coan; James J Vredenburgh
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Cancer 2012;118(5):1302-12.
2012: John H Sampson; Robert J Schmittling; James J Vredenburgh; Smita K Nair; Elizabeth A Reap; David A Reardon; Gary E Archer; Darell D Bigner; April Coan; Kendra L Congdon; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Duane A Mitchell
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
PloS one 2012;7(2):e31046.
2012: David A Reardon; John H Sampson; James J Vredenburgh; Patrick Y Wen; April Coan; Annick Desjardins; Jan Drappatz; Sridharan Gururangan; James E Herndon; Eric S Lipp; Roger E McLendon; Andrew D Norden; Julie A Norfleet; Katherine B Peters; Henry S Friedman
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Journal of neuro-oncology 2012;106(2):409-15.
2011: David A Reardon; Jeremy N Rich; Sith Sathornsumetee; James J Vredenburgh; April Coan; Annick Desjardins; Sridharan Gururangan; James E Herndon; Katherine B Peters; Henry S Friedman
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Journal of neuro-oncology 2011;105(3):621-7.
2011: Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Katherine B Peters; David A Reardon; Stevie Threatt; April D Coan; James J Vredenburgh
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Journal of neuro-oncology 2011;105(3):601-6.
2011: David A Reardon; John H Sampson; Stevie Threatt; James J Vredenburgh; April Coan; Annick Desjardins; Allan H Friedman; Sridharan Gururangan; James E Herndon; Roger E McLendon; Katherine B Peters; Henry S Friedman
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Cancer 2011;117(23):5351-8.
2011: Scott G Turner; James J Vredenburgh; Annick Desjardins; Henry S Friedman; Katherine B Peters; David A Reardon
Everolimus tablets for patients with subependymal giant cell astrocytoma.
Expert opinion on pharmacotherapy 2011;12(14):2265-9.
2011: Emily Ruden; James J Vredenburgh; Emily Waner; Miranda West; Katherine B Peters; David A Reardon; April D Coan; Annick Desjardins; Diane R Fels; Allan H Friedman; Henry S Friedman; James E Herndon; Whitney E Hornsby; Lee W Jones
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(21):2918-23.
2011: James J Vredenburgh; Leighann Bailey; Darell D Bigner; Annick Desjardins; Allan H Friedman; James E Herndon; John P Kirkpatrick; Jennifer Marcello; Katherine B Peters; David A Reardon; John H Sampson; Stevie Threatt; Henry S Friedman
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(12):4119-24.
2011: David A Reardon; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John Sampson; Jeremy Rich; Roger McLendon; James E Herndon; Jennifer Marcello; Stevie Threatt; Allan H Friedman; James J Vredenburgh; Henry S Friedman
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Journal of neuro-oncology 2011;103(2):371-9.
2011: David A Reardon; Scott Turner; Katherine B Peters; Annick Desjardins; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Lee W Jones; John P Kirkpatrick; Allan H Friedman; James J Vredenburgh; Darell D Bigner; Henry S Friedman
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(4):414-27.
2011: Charles W Kanaly; Dale Ding; Ankit I Mehta; Anthony F Waller; Ian Crocker; Annick Desjardins; David A Reardon; Allan H Friedman; Darell D Bigner; John H Sampson
A novel method for volumetric MRI response assessment of enhancing brain tumors.
PloS one 2011;6(1):e16031.
2011: Katherine B Peters; Thomas E Coyle; James J Vredenburgh; Annick Desjardins; Henry S Friedman; David A Reardon
Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.
Journal of neuro-oncology 2011;101(1):155-9.
2011: David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John H Sampson; Jennifer Marcello; James E Herndon; Roger E McLendon; Dorothea Janney; Allan H Friedman; Darell D Bigner; Henry S Friedman
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Journal of neuro-oncology 2011;101(1):57-66.
2010: Sith Sathornsumetee; Annick Desjardins; James J Vredenburgh; Roger E McLendon; Jennifer Marcello; James E Herndon; Alyssa Mathe; Marta Hamilton; Jeremy Rich; Julie A Norfleet; Sridharan Gururangan; Henry S Friedman; David A Reardon
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Neuro-oncology 2010;12(12):1300-10.
2010: Hamidreza Aliabadi; James J Vredenburgh; Richard G Everson; Annick Desjardins; Henry S Friedman; Roger E McLendon; Debara L Tucci; John H Sampson
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
Journal of neuro-oncology 2010;98(3):427-30.
2010: David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; Allan H Friedman; James E Herndon; Jennifer Marcello; Julie A Norfleet; Roger E McLendon; John H Sampson; Henry S Friedman
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Journal of neuro-oncology 2010;96(2):219-30.
2009: David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Sith Sathornsumetee; Roger E McLendon; James E Herndon; J E Marcello; J Norfleet; Allan H Friedman; Darell D Bigner; Henry S Friedman
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
British journal of cancer 2009;101(12):1986-94.
2009: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Journal of neuro-oncology 2009;95(3):393-400.
2009: Stephanie L Perry; Cindy Bohlin; David A Reardon; Annick Desjardins; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
Journal of neuro-oncology 2009;95(1):129-34.
2009: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Neuro-oncology 2009;11(5):556-61.
2009: Mary Lou Affronti; Christopher R Heery; James E Herndon; Jeremy Rich; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; Darell D Bigner; Henry S Friedman
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Cancer 2009;115(15):3501-11.
2009: Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman
Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.
Journal of neuro-oncology 2009;94(1):79-85.
2009: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Cancer 2009;115(13):2964-70.
2009: David A Reardon; Merrill J Egorin; Annick Desjardins; James J Vredenburgh; Jan H Beumer; Theodore F Lagattuta; Sridharan Gururangan; James E Herndon; August J Salvado; Henry S Friedman
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Cancer 2009;115(10):2188-98.
2009: James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Experience with irinotecan for the treatment of malignant glioma.
Neuro-oncology 2009;11(1):80-91.
2008: Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7068-73.
2008: Sridharan Gururangan; Jeanne Krauser; Melody Watral; Tim Driscoll; Nicole Larrier; David A Reardon; Jeremy Rich; Jennifer A Quinn; James J Vredenburgh; Annick Desjardins; Roger E McLendon; Herbert Fuchs; Joanne Kurtzberg; Henry S Friedman
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
Neuro-oncology 2008;10(5):745-51.
2008: David A Reardon; Annick Desjardins; James J Vredenburgh; Sith Sathornsumetee; Jeremy Rich; Jennifer A Quinn; Theodore F Lagattuta; Merrill J Egorin; Sridharan Gururangan; Roger E McLendon; James E Herndon; Allan H Friedman; August J Salvado; Henry S Friedman
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Neuro-oncology 2008;10(3):330-40.
2008: Richard G Everson; Michael W Graner; Matthias Gromeier; James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman; Allan H Friedman; Darell D Bigner; John H Sampson
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Expert review of anticancer therapy 2008;8(5):717-32.
2008: David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Expert opinion on biological therapy 2008;8(4):541-53.
2008: David A Reardon; Michael R Zalutsky; Gamal Akabani; R Edward Coleman; Allan H Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; Jennifer A Quinn; Jeremy Rich; James J Vredenburgh; Annick Desjardins; Sridharan Guruangan; Susan Boulton; Renee H Raynor; Jeannette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Henry S Friedman; Darell D Bigner
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Neuro-oncology 2008;10(2):182-9.
2008: David A Reardon; Annick Desjardins; Jeremy Rich; James J Vredenburgh
The emerging role of anti-angiogenic therapy for malignant glioma.
Current treatment options in oncology 2008;9(1):1-22.
2008: Sith Sathornsumetee; Yiting Cao; Jennifer E Marcello; James E Herndon; Roger E McLendon; Annick Desjardins; Henry S Friedman; Mark Dewhirst; James J Vredenburgh; Jeremy Rich
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):271-8.
2007: James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4722-9.
2007: Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary Lou Affronti; Henry S Friedman
Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.
Therapeutics and clinical risk management 2007;3(5):707-15.
2007: Sith Sathornsumetee; David A Reardon; Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Jeremy Rich
Molecularly targeted therapy for malignant glioma.
Cancer 2007;110(1):13-24.
2007: Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Sith Sathornsumetee; Allan H Friedman; James E Herndon; Roger E McLendon; James M Provenzale; Jeremy Rich; John H Sampson; Sridharan Gururangan; Jeannette M Dowell; August Salvado; Henry S Friedman; David A Reardon
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Journal of neuro-oncology 2007;83(1):53-60.
2007: Sridharan Gururangan; Michael J Fisher; Jeffrey C Allen; James E Herndon; Jennifer A Quinn; David A Reardon; James J Vredenburgh; Annick Desjardins; Peter C Phillips; Melody Watral; Jeanne M Krauser; Allan H Friedman; Henry S Friedman
Temozolomide in children with progressive low-grade glioma.
Neuro-oncology 2007;9(2):161-8.
2007: Sith Sathornsumetee; Annick Desjardins; David A Reardon; Jeremy Rich; James J Vredenburgh
Neurofibromatosis type 2.
Neurology 2007;68(13):E14.
2007: James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1253-9.
2007: Michael A Badruddoja; Kara Penne; Annick Desjardins; David A Reardon; Jeremy Rich; Jennifer A Quinn; Sith Sathornsumetee; Allan H Friedman; Darell D Bigner; James E Herndon; Ann Cahill; Henry S Friedman; James J Vredenburgh
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Neuro-oncology 2007;9(1):70-4.
2006: David A Reardon; Jennifer A Quinn; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; James M Provenzale; Jeannette M Dowell; Jeremy Rich; James J Vredenburgh; Annick Desjardins; John H Sampson; Sridharan Gururangan; Terence Z Wong; Michael A Badruddoja; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(6):912-8.
2006: David A Reardon; Jennifer A Quinn; James J Vredenburgh; Sridharan Gururangan; Allan H Friedman; Annick Desjardins; Sith Sathornsumetee; James E Herndon; Jeannette M Dowell; Roger E McLendon; James M Provenzale; John H Sampson; Robert P Smith; Alan J Swaisland; Judith S Ochs; Peggy Lyons; Sandy Tourt-Uhlig; Darell D Bigner; Henry S Friedman; Jeremy Rich
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):860-8.
2006: David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; James M Provenzale; Jennifer A Quinn; Jeremy Rich; James J Vredenburgh; Annick Desjardins; Sridharan Gururangan; Sri Guruangan; Michael A Badruddoja; Jeannette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Michael R Zalutsky; Darell D Bigner
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):115-22.
2005: David A Reardon; Merrill J Egorin; Jennifer A Quinn; Jeremy Rich; Jeremy N Rich; Sridharan Gururangan; Idharan Gururangan; James J Vredenburgh; Annick Desjardins; Sith Sathornsumetee; James M Provenzale; James E Herndon; Jeannette M Dowell; Michael A Badruddoja; Roger E McLendon; Theodore F Lagattuta; Kimberly P Kicielinski; Gregor Dresemann; John H Sampson; Allan H Friedman; August J Salvado; Henry S Friedman
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9359-68.
2005: Jennifer A Quinn; Annick Desjardins; Jon D Weingart; Henry Brem; M Eileen Dolan; Shannon M Delaney; James J Vredenburgh; Jeremy Rich; Allan H Friedman; David A Reardon; John H Sampson; Anthony E Pegg; Robert C Moschel; Robert Birch; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Janet E Dancey; Jill Maxwell; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7178-87.
2005: David A Reardon; Jennifer A Quinn; Jeremy Rich; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; Sith Sathornsumetee; Michael A Badruddoja; Roger E McLendon; James M Provenzale; James E Herndon; Jeannette M Dowell; Jill L Burkart; Herbert B Newton; Allan H Friedman; Henry S Friedman
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Cancer 2005;104(7):1478-86.
2005: Annick Desjardins; Jeremy Rich; Jennifer A Quinn; James J Vredenburgh; Sridharan Gururangan; Sith Sathornsumetee; David A Reardon; Allan H Friedman; Darell D Bigner; Henry S Friedman
Chemotherapy and novel therapeutic approaches in malignant glioma.
Frontiers in bioscience : a journal and virtual library 2005;10():2645-68.